Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

Income Statement

Follow revenue through to earnings.

Revenue

$236.20M

FY 2025 · Annual

+47.5% YoY

Operating Income

$23.50M

FY 2025 · Annual

Net Income

-$5.34M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

AKBA Earnings Waterfall · TTM

NASDAQ:AKBA · Revenue to Net Income

Key Ratios

EPS$-0.08
Gross Margin80.7%
Net Margin-9.2%
P/E Ratio320.8
P/S Ratio10.5

Analysis

$232.4M of revenue converted into -$20.5M of net income for the selected period. Gross margin is 80.7% and net margin is -9.2%, showing how much revenue survives after costs and taxes. EPS is $-0.08, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportOct 23, 2026
8-KCurrent reportOct 14, 2026
4Statement of changes in beneficial ownershipAug 10, 2026

How much revenue does AKBA generate?

Akebia Therapeutics, Inc. (AKBA) reported $236.20M of revenue in fiscal 2025.

Is AKBA profitable?

Akebia Therapeutics, Inc. (AKBA) reported -$5.34M of net income, with a net margin of -2.3%.